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Cleavage of C3 to C3a and C3b plays a central role in the generation of 26 
complement-mediated defences. Although the thioester-mediated surface deposition 27 
of C3b has been well-studied, fluid-phase dimers of C3 fragments remain largely 28 
unexplored. Here we show C3 cleavage results in the spontaneous formation of C3b 29 
dimers and present the first X-ray crystal structure of a disulphide-linked human C3d 30 
dimer. Binding studies reveal these dimers are capable of crosslinking complement 31 
receptor 2 and preliminary cell-based analyses suggest they could modulate B cell 32 
activation to influence tolerogenic pathways. Altogether, insights into the 33 
physiologically-relevant functions of C3d(g) dimers gained from our findings will pave 34 
the way to enhancing our understanding surrounding the importance of complement 35 
in the fluid phase and could inform the design of novel therapies for immune system 36 




Activation of the central complement component C3 (~1 mg mL-1) to C3a and C3b by 39 
classical/lectin (C4bC2a) or alternative (C3bBb) pathway C3 convertases plays an 40 
essential role in the generation of complement-mediated defence mechanisms 41 
against invading microbial pathogens. While the circulating C3a anaphylatoxin is 42 
involved in inducing inflammatory immune responses, C3b (reported1 normal plasma 43 
concentration: ~210 ng mL-1  but levels are markedly higher on infection and under 44 
certain disease conditions although its short half-life (< 2 min) makes accurate 45 
measurements difficult) facilitates opsonophagocytosis and clearance of immune 46 
complexes through thioester-mediated opsonisation of primary amine- or hydroxyl-47 
containing antigenic and self surfaces. Attachment of multiple copies of C3b and its 48 
breakdown products to antigenic surfaces in this way can result in C3d-complement 49 
receptor 2 (CR2/CD21) and antigen-B cell receptor (BCR) co-ligation which 50 
generates co-stimulatory signals for B cell activation in a C3d copy-dependent 51 
manner2,3 and has been widely explored in vaccine design4-9.  52 
 53 
Structure determination of native C3, C3b and C3c has provided crucial insights into 54 
the mechanistic basis behind the activation of C3 to C3b10,11 while complexes of C3b 55 
with factor I (FI) and the short consensus repeat (SCR) domains 1-4 of its cofactor 56 
factor H (FH1-4) have revealed the processes through which C3b is proteolytically 57 
cleaved into its successive opsonin fragments iC3b and C3dg12 (normal plasma 58 
concentration: < 5.3 µg mL-1, half-life: 4 hours13). Crystal structures have also shed 59 
light upon the molecular basis underlying the thioester-mediated attachment of C3d 60 
to antigenic surfaces14, provided explanations of how the interactions of C3d with its 61 
receptors (CR215 and CR316) facilitate the recognition of opsonised antigens, and the 62 
mechanisms by which pathogens such as Staphylococcus aureus utilise C3d-binding 63 
proteins (e.g. Sbi17, Efb-C18,19 and Ecb/Ehp20,21) to inhibit these interactions and 64 
evade the immune system. Furthermore, complexes of C3d with FH SCR domains 65 
19 and 20, which also bind host surface polyanionic markers such as 66 
glycosaminoglycans and sialic acids, have been pivotal in understanding the 67 
regulatory measures in place to protect host tissues against the indiscriminate 68 




However, while these seminal structural studies alongside an abundance of 71 
functional investigations have advanced our knowledge surrounding the interaction 72 
of C3 fragments with self and non-self surfaces at a molecular level, our 73 
understanding of the structural and functional aspects of fluid phase C3 activation 74 
products remains incomplete. During activation in the fluid phase, the majority of C3 75 
molecules do not covalently attach to surface-exposed hydroxyl- or amine-76 
nucleophiles but instead the highly reactive Cys–Gln thioester moiety within the 77 
thioester-containing C3d domain (TED) of C3 undergoes hydrolysis resulting in the 78 
generation of C3(H2O) and formation of the C3(H2O)Bb alternative pathway (AP) C3 79 
convertase. Of the C3b generated by these fluid phase or surface-associated 80 
convertases, only approximately 10% is deposited onto reactive surfaces24, leaving 81 
the remaining 90% to react with water wherein exposure of the cysteine free 82 
sulfhydryl can lead to dimerisation of C3b and its subsequent breakdown products 83 
iC3b and C3d(g) . Evidence of these dimers has been demonstrated via visualisation 84 
of C3b generated from trypsin digestion of serum-derived C3 under non-reducing 85 
conditions25 and in C3dg preparations purified from human serum following ‘aging’ at 86 
37 °C for 7 days26.  87 
 88 
C3b dimers, formed either by disulphide bonds or via other, undefined interactions, 89 
have also been found to bind CR1 with 25-fold higher affinity than monomeric C3b25, 90 
induce histaminase release from human polymorphonuclear leukocytes26, serve as 91 
binding platforms for factor B fragment Bb during formation of AP C5 92 
convertases27,28 and act as potent AP activators in complex with IgG29. In addition, 93 
dimers of C3dg have been isolated from C3-activated human serum following 94 
omission of N-ethylmaleimide30 and the propensity of recombinant C3d to dimerise 95 
has been reported previously31,32. A crystal structure of dimeric C3dg purified from 96 
rat serum33 provides further crucial evidence of the endogenous existence of these 97 
dimers. However, aside from this severely truncated C3dg dimer which is believed to 98 
have undergone proteolytic truncation during the crystallisation process34, there is 99 
currently a gap in knowledge surrounding the structural significance of disulphide-100 
linked dimers of C3 fragments as the thioester cysteine sulfhydryl is routinely 101 
removed prior to structural analyses. For instance, the free cysteine of C3b has been 102 
reacted with iodoacetamide prior to structural determination11,35,36 and the vast 103 
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majority of C3d constructs used for structural studies to date have harboured a 104 
cysteine to alanine substitution in order to prevent dimerisation14,15,22,23. 105 
 106 
In this study we therefore aimed to delineate the molecular details and explore the 107 
functional significance of dimeric human C3 fragments that can form following 108 
activation of C3 in the fluid phase. We provide confirmatory evidence showing the 109 
formation of disulphide-linked C3b dimers derived from serum-derived C3 and 110 
subsequently present the first crystal structure of a human C3d dimer at 2.0 Å where 111 
dimerisation is mediated by disulphide linkage of the thioester cysteine residues. 112 
Through surface plasmon resonance (SPR) binding studies and preliminary cell 113 
experiments using mouse splenocytes and human peripheral blood mononuclear 114 
cells (PBMC) we show how dimeric C3d crosslinks surface-bound CR2 and could 115 
modulate B cell activation to potentially influence tolerance mechanisms. In the 116 
future a deeper understanding of these newly-discovered physiologically-relevant 117 
roles of C3 fragment dimers could inform the design of autoimmune therapies and 118 
help to further elucidate the significance of complement in the fluid phase as it 119 
interacts with cells of the adaptive immune system and beyond. 120 
 121 
  122 
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Results  123 
To elucidate the importance of dimeric human C3 breakdown fragments, we 124 
investigated the formation of disulphide-linked dimers of C3b and C3d through 125 
limited trypsin proteolysis of C3 and subsequently analysed the structural 126 
characteristics of dimeric C3d using X-ray crystallography. SPR was used to 127 
compare the binding kinetics and avidity of these dimers and monomeric C3d to CR2 128 
and FH19-20 and C3d-induced changes in the activation state of B cells were explored 129 
using flow cytometric analyses. 130 
 131 
Cleavage of C3 results in the spontaneous formation of disulphide-linked C3b 132 
dimers  133 
C3 purified from human serum was cleaved with trypsin under mild proteolysis 134 
conditions and subsequently analysed using SDS-PAGE and anti-C3 -chain 135 
western blotting (Figure 1). Over 50% of C3 is cleaved to C3b following digestion 136 
with trypsin after 2 minutes (Figure 1a) and a significant fraction of this C3b, 137 
visualised under non-reducing conditions, spontaneously forms disulphide-bonded 138 
dimers (Figure 1b). These dimers form instantly and remain stable for at least 2 139 
hours (Supplementary Figure S1). In addition to the C3b dimers, a weak higher 140 
molecular weight band suggestive of a dimeric form of C3 can also be observed at 141 
t=0. The absence of these dimers in samples treated with reducing agent indicates 142 
their formation is mediated by disulphide bonds. In a similar manner, recombinant 143 
wild-type human C3d, with its native thioester cysteine intact (C3d17C), also forms 144 
disulphide-linked dimers under non-reducing conditions (Supplementary Figure 145 
S2).  146 
 147 
Disulphide linkage of the thioester cysteine results in C3d dimerisation  148 
A crystal structure of wild-type human C3d, harbouring a cysteine at position 149 
17/1010 (C3d numbering/intact pre-pro C3 numbering) (C3d17C), was obtained at 2.0 150 
Å resolution (Figure 2, Supplementary Tables S1 and S2). The structure clearly 151 
shows the formation of a dimer mediated by partial disulphide linkage of the thioester 152 
6 
 
cysteine residues at position 17/1010 in both monomeric chains. This 17C-17C 153 
disulphide creates a link between the two C3d monomers at the C-terminus of helix 154 
α1, causing the convex molecular surfaces of the monomers to orient towards each 155 
other whilst simultaneously exposing their concave binding faces (Figure 2a). Closer 156 
examination of the C3d17C dimer interaction surface (Figure 2b) confirms that the 157 
overall (α-α)6 barrel configuration of both monomers remains unchanged and 158 
comparable to previously-published structures of monomeric C3d (0.61 Å (chain 159 
A)/0.40 Å (chain B) main chain (M1-P294) RMSD relative to PDB: 1C3D). The 2Fo-160 
Fc electron density map at the C3d17C dimer interface shows that chain B residue 161 
17C (Figure 2b inset) adopts a dual conformation with one conformer existing in an 162 
unpaired oxidized form, perhaps due to radiation damage. This indicates the 163 
disulphide bond linking the two C3d monomers can occur in a partially disconnected 164 
state which is consistent with results from size exclusion chromatography 165 
experiments suggesting C3d17C exists in a monomer-dimer equilibrium in solution 166 
(Supplementary Figure S2). 167 
 168 
Superimposition of the ligand-binding domains of CR2 (SCR1-2), the αMI integrin 169 
domain of CR3 or SCRs 19-20 of FH on to the dimeric C3d17C structure fails to 170 
generate any molecular clashes (Supplementary Figures S3a-d). This important 171 
observation suggests dimerisation does not cause any interference in the formation 172 
of complexes between C3d or C3dg and their most physiologically-relevant binding 173 
partners. Staphylococcus aureus immune evasion proteins such as Efb-C, Ecb/Ehp 174 
and Sbi-IV are also predicted to bind the C3d17C dimer without any hindrance as the 175 
concave surfaces of both monomers are exposed and accessible. Significantly, as 176 
CR2 and CR3 interact with the C3d17C dimer via opposing surfaces, complement 177 
receptor crosslinking could play an important role in the function of C3d dimers 178 
(Supplementary Figure S3c). Moreover, the absence of steric hindrance following 179 
superimposition of the C3d17C dimer onto the C3b TED domain (Supplementary 180 
Figure S3e), suggests dimerisation of C3b, as proposed previously37,38, could occur 181 
in a similar fashion to C3d without affecting the ability of C3b to interact with the 182 
complement regulators FH and FI.  183 
 184 
C3d dimers can crosslink CR2 and FH19-20 185 
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As our structural analyses revealed the propensity of C3d17C to dimerise, we next 186 
analysed the binding interactions of C3d dimers in comparison to monomeric C3d17A 187 
using CR2 and FH19-20 as two important known binding partners. Given that our size 188 
exclusion chromatography experiments (Supplementary Figure S2) showed that 189 
monomeric and dimeric C3d exist in equilibrium and therefore dimers can readily 190 
dissociate into their monomeric constituents, we opted to create chemically stable 191 
dimers of C3d17C conjugated at the 17C position via a bromine-based linear linker 192 
(N,N'-(propane-1,3-diyl) bis(2-bromoacetamide), see Materials and Methods; 193 
Supplementary Figures S4-S6b). The N,N'-(propane-1,3-diyl) bis(2-194 
bromoacetamide) linker was used as this class of chemical compound has been 195 
shown to selectively crosslink cysteine residues located within close spatial 196 
proximity39. Dimeric C3d17C resulting from this chemical crosslinking reaction was 197 
subsequently validated using particle analysis (Supplementary Figure S6c), 198 
analytical ultracentrifugation (Supplementary Figure S6d) and mass spectrometry 199 
(Supplementary Tables S3 and S4, Supplementary Figure S6e) and utilised in 200 
SPR spectroscopy studies to gain insights into its binding patterns and kinetics. 201 
 202 
In contrast to monomeric C3d17A which displays a conventional association-steady 203 
state-dissociation binding pattern when flowed over surface-immobilised CR2-Fc and 204 
FH19-20 (Figure 3a left), the binding of dimeric C3d17C to the same ligands was found 205 
to be noticeably distinct and suggestive of a two-state binding interaction (Figure 3a 206 
right). At low concentrations up to the first replicate of 15.63 nM (dashed line), the 207 
highly avid interactions with negligible dissociation indicate a bivalent binding mode 208 
whereby the C3d17C dimer crosslinks two CR2-Fc or two FH19-20 molecules. During 209 
the first injection of 15.63 nM C3d17C dimer, 25 RU of material binds to the surface 210 
and 10 RU remain avidly bound to the surface after regeneration. While at the 211 
second 15.63 nM injection, 18 RU of material binds to the surface and only 2RU 212 
remains avidly bound at the end (Supplementary Figure S7). In both cases an 213 
equivalent amount of material is eluted during regeneration indicating the first 214 
injection likely saturates the highly avid binding sites. As the surface cannot be fully 215 
regenerated of these high avidity complexes, the subsequent cycle commences at a 216 
higher baseline response. At this point and higher concentrations, the high avidity 217 
binding sites for dimeric C3d17C on CR2-Fc or FH19-20 remain saturated causing the 218 
binding mode to switch to less favourable/avid readily-disrupted interactions 219 
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suggestive of 1:1 binding between the C3d17C dimer and CR2-Fc or FH19-20 although 220 
some cross-linked C3d17C dimer-CR2-Fc and C3d17C dimer- FH19-20 complexes 221 
persist (1-2 RU of material remaining bound to the surface after regeneration). At the 222 
highest three concentrations of dimeric C3d17C (62.5-250 nM), the less favourable 223 
1:1 interactions (between 1 C3d17C dimer: 1 CR2-Fc or FH19-20 molecule) which are 224 
readily eluted from the surface dominate (Figure 3a right inset). Consistent with 225 
these results, the unusual binding patterns observed here were also evident in a 226 
further two independent experiments (Supplementary Figure S8) and cannot be 227 
attributed to higher order species of analyte or ligand as biophysical techniques 228 
showed the dimeric C3d17C and FH19-20 preparations used did not contain aggregates 229 
(Supplementary Figures S6c, S6d and S9). A model illustrating the binding events 230 
described here is presented in Figure 3b (for CR2-Fc) and the superposition 231 
displayed in Figure 3c illustrates the feasibility of CR2 crosslinking by dimeric 232 
C3d17C at a structural level. 233 
 234 
Dimeric C3d is a more potent modulator of B cell activation than monomeric 235 
C3d 236 
Following on from our SPR studies which indicated dimeric C3d may have the 237 
capacity to crosslink CR2, our next aim was to analyse the effects of dimeric 238 
compared to monomeric C3d on B cell activation. Flow cytometry was employed to 239 
examine changes in the expression of four surface-associated B cell activation 240 
markers (CD40, CD69, CD71 and CD86) resulting from stimulation of isolated 241 
human B cells with monomeric C3d17A or chemically-linked dimeric C3d17C alone or 242 
in the presence of BCR-crosslinking anti-IgM F(ab’)2. As shown in Supplementary 243 
Figure S10, although agonism of the BCR by anti-IgM significantly enhances 244 
expression of all the activation markers (except CD40), neither monomeric C3d17A 245 
nor dimeric C3d17C appears to influence the activation of isolated B cells in an 246 
appreciable manner, as measured by the markers examined.  247 
 248 
A more general approach, using Ca2+ influx as a measure of B cell activation was 249 
therefore taken next. Here, incubation of B220+ mouse splenocytes with monomeric 250 
C3d17A or dimeric C3d17C prior to stimulation with a suboptimal dose of a biotinylated- 251 
anti-IgM/C3dg-biotin/streptavidin (a-IgM-b/C3dg-b/ST) BCR/CR2-crosslinking 252 
complex was found to inhibit BCR/CR2-mediated Ca2+ influx in a concentration-253 
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dependent manner (Figure 4a, Supplementary Figure S11). The observed blocking 254 
effect was more pronounced following treatment with dimeric C3d17C, particularly at 255 
the lower concentration of 4 µg (Figure 4a), and for both constructs is only evident 256 
when C3d is added ahead of the a-IgM-b/C3dg-b/ST complex and when a 257 
suboptimal dose of anti-IgM (i.e. unable to trigger Ca2+ influx in the absence of CR2 258 
engagement) within the crosslinking complex is used. Thus, the perceived inhibition 259 
of Ca2+ influx and hence B cell activation is likely to result from sequestration of CR2 260 
by monomeric C3d17A, and to a greater extent, due to avidity and possibly via CR2-261 
CR2 crosslinking as suggested by our SPR experiments, dimeric C3d17C, reducing 262 
the proportion of CR2 available for crosslinking with the BCR. 263 
 264 
In order to further investigate C3d-mediated changes in the activation state of B cells 265 
within mixed populations of cells, as would occur in vivo, flow cytometry was utilised 266 
to explore differences in the expression of CD40, CD69, CD71 and CD86 on CD19+ 267 
cells within donor human PBMC samples (see Supplementary Figures S12 and 268 
S13 for gating strategy applied). In contrast to the results gathered from isolated 269 
human B cells (Supplementary Figure S10), a clear dose-dependent relationship 270 
between C3d and B cell activation was observed in these experiments indicating in B 271 
cell other mononuclear cell types may be involved responsiveness to free C3d, as 272 
measured by expression of the markers analysed (Figure 4b). At concentrations > 273 
10 nM, both monomeric C3d17A and chemically-linked dimeric C3d17C are able to 274 
enhance expression of the early B cell activation markers CD69 and CD86 even in 275 
the absence of BCR engagement by anti-IgM. In concert with anti-IgM although both 276 
forms of C3d synergistically upregulate expression of these markers in a 277 
concentration-dependent manner, dimeric C3d17C is found to be approximately three-278 
fold more effective at enhancing activation than monomeric C3d17A (47nM vs 139 nM 279 
(CD69) and 18 nM vs 59 nM (CD86) geometric mean EC50s), perhaps through more 280 
avid interactions with CR2. 281 
 282 
Interestingly, in contrast to CD69 and CD86, both monomeric C3d17A and dimeric 283 
C3d17C appear to downregulate CD40, particularly in the presence of anti-IgM, with a 284 
more pronounced reduction in expression evident in the presence of dimeric C3d17C. 285 
Differently still, despite achieving a substantial increase in expression in the 286 
presence of anti-IgM in the experimental time period, CD71 does not appear to be 287 
10 
 
influenced by either form of C3d. Importantly, the differential marker-specific trends 288 
observed are consistent across cells gathered from all three donors analysed (data 289 
from donors 2 and 3 can be found in Supplementary Figure S14) suggesting free 290 
C3d (unattached to an antigen) may regulate B cell activation in a selective manner 291 




Pre-treatment of C3b with sulfhydryl-alkylating agents and routine use of a 294 
recombinant thioester cysteine deletion construct (C17A) in the past has prohibited 295 
the structural and functional analysis of disulphide-linked dimers of C3 fragments 296 
that can form following activation in the fluid phase. Concurrent with previous 297 
findings25, in this study we provide evidence showing trypsin-mediated cleavage of 298 
C3 results in the spontaneous formation of a significant fraction of disulphide-linked 299 
C3b dimers (Figure 1). Interestingly, our results additionally suggest the formation of 300 
a dimeric form of C3. This dimeric fraction could conceivably involve the hydrolysed 301 
form of C3 (C3(H2O)) in which the exposed thioester cysteine sulphydryl renders it 302 
prone to the formation of disulphide-linked dimers as observed with C3b25 as well as 303 
the related thioester-containing complement protein fragments C4Ab and C4Bb40.  304 
 305 
Furthermore, here we verify that C3 breakdown product C3d, with its native thioester 306 
cysteine intact (C3d17C), forms disulphide-linked dimers in an analogous fashion to 307 
C3b and in the first X-ray crystal structure of a human C3d dimer we confirm that 308 
dimerisation is mediated by disulphide linkage of the thioester cysteine residues at 309 
position 17/1010 (C3d numbering/intact pre-pro C3 numbering) (Figure 2) in a 310 
manner that would also permit the analogous dimerisation of C3b (Supplementary 311 
Figure S3e). Importantly, this dimer retains the ability of C3d to bind SCR domains 312 
1-2 of CR2, the αMI integrin domain of CR3 and SCR domains 19-20 of FH 313 
(Supplementary Figures S3a-d).  314 
 315 
In order to complement our structural studies, we next analysed the binding of a 316 
stable chemically-linked C3d17C dimer (Supplementary Figures S5 and S6) to CR2 317 
(SCR1-4) and FH19-20 using SPR. Here dimeric C3d17C showed higher avidity binding 318 
to both of the interacting partners examined, and in contrast to monomeric C3d, was 319 
found to crosslink surface-associated CR2 as well as FH19-20 (Figure 3, 320 
Supplementary Figures S7 and S8). This crosslinking by disulphide-linked C3d17C 321 
dimers cannot be explained by the formation of higher order aggregates of dimeric 322 
C3d17C (Supplementary Figures S6c and S6d) or FH19-20 (Supplementary Figure 323 
S9) and is a finding that has not been observed previously but could indicate a 324 
potential physiologically-relevant role of these dimers. Future investigations will 325 
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elucidate whether dimeric C3d17C can crosslink its other receptor, CR3, or a 326 
combination of CR2 and CR3, as suggested by our structural superpositions 327 
(Supplementary Figures S3b and S3c).   328 
 329 
Finally, we investigated the effects of dimeric compared to monomeric C3d on the 330 
activation state of primary human and murine B cells using flow cytometry and Ca2+ 331 
influx experiments. In contrast to results from resting tonsillar B cells41, when 332 
assayed in isolation, we found B cells purified from human PBMCs appeared to be 333 
unresponsive to both forms of free C3d (Supplementary Figure S10). However, 334 
both monomeric C3d17A, and to a greater extent dimeric C3d17C, inhibited BCR/CR2-335 
mediated Ca2+ influx in B220+ murine splenocytes when added prior to stimulation 336 
with a BCR/CR2-crosslinking complex (Figure 4a and Supplementary Figure S11). 337 
Further to previous reports using biotinylated C3dg (with a C17A mutation) in the 338 
presence of streptavidin41,42, these results suggest that pre-ligation of CR2 by 339 
naturally-occurring fluid phase C3d(g) dimers could inhibit BCR/CR2 crosslinking-340 
mediated Ca2+ responses in B cells by sequestering the CR2/CD19/CD81 receptor 341 
complex from the BCR with higher avidity than C3d monomers.  342 
 343 
Both dimeric and monomeric C3d were also found to induce changes in the 344 
expression of B cell activation markers on human CD19+ cells within PBMC samples 345 
(Figure 4b, Supplementary Figure S14). Specifically, in the presence of anti-IgM, 346 
both monomeric C3d17A and to a three-fold greater extent dimeric C3d17C, 347 
synergistically upregulated CD69 and CD86 which is consistent with previous reports 348 
showing independent ligation of CR2 and the BCR (i.e. without crosslinking) by 349 
simultaneous stimulation with biotinylated-C3dg/streptavidin complexes and anti-IgM 350 
can augment B cell activation43. Our results, however, additionally show that dimeric 351 
C3d17C is more efficient at augmenting CR2/BCR-dependent activation and that BCR 352 
engagement may not be necessary for upregulation of certain activation makers as 353 
at higher concentrations both forms of C3d were also capable of enhancing 354 
expression of the early activation markers CD69 and CD86 in the absence of anti-355 
IgM. Although these findings in human PBMCs differ from a recent report suggesting 356 
C3d inhibits the BCR-induced expression of CD69 on isolated tonsillar B cells41, they 357 
are likely more representative of in vivo conditions, where interactions between 358 




In contrast to CD69 and CD86, both monomeric and dimeric C3d appeared to 361 
downregulate CD40, with a more pronounced reduction in expression in the 362 
presence of dimeric C3d17C. CD40 is involved in the regulation of several B cell 363 
processes including germinal centre reactions44, isotype switching45 and somatic 364 
hypermutation46 and has also been shown to prevent B cells from becoming 365 
anergic47. Although further investigations are required to explain the C3d-mediated 366 
downregulation of CD40 expression on B cells observed in our study, it is possible 367 
that C3d stimulation of CR2 or CR3 expressed on other PBMC cell types (e.g. T 368 
cells48-51 and natural killer cells52) induces the production of higher levels of soluble 369 
CD40L that drive internalisation of CD40 or prevent efficient staining by occluding 370 
the receptor. Alternatively, the known binding of CD40L to CR353 could be 371 
outcompeted by CR3 interactions with C3d, particularly in its dimeric form, elevating 372 
the levels of soluble CD40L available for binding CD40. Further experiments 373 
investigating the effects of free monomeric and dimeric C3d on IgG titre and hence 374 
B-cell differentiation or antibody class switching following activation of PBMCs with T 375 
cell supernatants or co-culture with IL-2 or CD40L-producing feeder cells will help to 376 
understand this process further. 377 
  378 
Nonetheless, the preliminary data presented here suggest fluid-phase C3d(g), 379 
particularly in its dimeric form, could alter the activation of B cells and may direct 380 
them towards an anergic state. Although further verification is required, this 381 
proposed role would be logical in terms of helping to limit the involvement of 382 
complement in the generation of humoral immune responses in the absence of a 383 
threat and is consistent with reports of CR2 ligation being involved in the anergy of 384 
autoreactive B cells43,54,55. Thus, in the future, C3d(g) dimers could have implications 385 
for the development of novel therapies for autoimmune diseases, for example 386 
through their effects on CD40/CD40L interactions, particularly as downregulation of 387 
CD40 was shown to be a beneficial outcome of Rituximab treatment of systemic 388 
lupus erythematosus (SLE) patients56 and CD40/CD40L levels have been linked to 389 
anti-DNA autoantibody titres in lupus patients57 and mouse models58. By extension, 390 
these newly-uncovered functions of C3d could also offer a possible explanation as to 391 
why humoral immune responses are inhibited, rather than enhanced, by certain 392 
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vaccine constructs composed of antigens linked to linear repeats of C3d placed in 393 
close proximity to each other43,59. 394 
 395 
On the whole, our cell experiments not only suggest free fluid-phase C3d(g) 396 
(unattached to a surface) may regulate B cell activation in a selective manner but 397 
also that there are clear functional differences between monomeric and dimeric C3d 398 
with the latter being a more potent modulator of the activation state of B cells as a 399 
consequence of high avidity receptor interactions or through receptor crosslinking. In 400 
addition, they indicate other PBMC cell types play an important role in the 401 
responsiveness of B cells, in terms of the activation markers analysed, to C3d, 402 
perhaps through the provision of sensitising or synergising co-stimulatory molecules 403 
or via CR2-CR2 or CR2-CR3 crosslinking between cells. Although these preliminary 404 
experiments have brought to light some of the potentially physiologically-relevant 405 
functions of fluid-phase C3d(g) dimers, further investigations probing the molecular 406 
mechanisms underlying these roles are warranted. In a wider context, it would also 407 
be interesting to explore possible connections between the levels of C3d(g) dimers, 408 
their distribution in the body and pathological conditions associated with uncontrolled 409 
C3 activation, such as C3 glomerulopathy, as we surmise local upregulation of fluid 410 
phase C3d(g) concentrations is likely to enhance C3d(g) dimerisation.  411 
 412 
In summary, in this study we reaffirm the spontaneous formation of disulphide-linked 413 
C3b dimers following cleavage of C3 and present the first structure of a fluid-phase 414 
disulphide-linked human C3d dimer. Through accompanying functional analyses we 415 
show that these dimers could have physiologically-relevant roles in crosslinking CR2 416 
and selectively modulating B cell activation, possibly to trigger tolerogenic pathways.  417 
Overall, our findings shed light on a fundamental aspect of complement biology that 418 
is often overlooked and could have the potential to inform the design of novel 419 
therapeutics for immune system disorders in the future.   420 
  421 
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Materials and Methods 422 
 423 
Purification and mild trypsin proteolysis of human C3 424 
C3 was purified from human serum by PEG precipitation60, by slowly mixing the 425 
serum with PEG 4000 (in precipitation buffer: 100 mM sodium phosphate, 150 mM 426 
NaCl, 15 mM EDTA, 0.5 mM PMSF, pH 7.4) to a final concentration of 5% and then 427 
incubating the mixture on ice for 30 mins. After centrifugation, the supernatant was 428 
retained, and the process was repeated using PEG 4000 at a final concentration of 429 
12%. The resulting pellet was resuspended in binding buffer and purified by weak 430 
anion exchange chromatography (column: 1mL HiTrap DEAE Sepharose FF 431 
(Cytiva), binding buffer: 25 mM potassium phosphate, 5 mM EDTA, 50 mM EACA, 432 
pH 7.0, elution buffer: 25 mM potassium phosphate, 5 mM EDTA, 50 mM EACA, 300 433 
mM NaCl, pH 7.0).   434 
The C3 containing fractions were subsequently pooled and 100 µg was digested with 435 
Trypsin Gold protease (Promega) at 37°C for 2 mins before being quenched with 3% 436 
(w/w) soybean trypsin inhibitor (Sigma Aldrich). An additional t=0 sample was 437 
prepared by adding trypsin and trypsin inhibitor at the same time to a sample 438 
containing 10 µg C3 before the incubation. The digested protein was then incubated 439 
at 18°C for 2 hours, with timepoints taken every 15 mins and analysed using 440 
reducing and non-reducing tris-acetate SDS-PAGE. 441 
For western blot analyses, PVDF membrane was initially washed in methanol and 442 
then soaked in western blot transfer buffer (methanol-free, Pierce) along with the gel 443 
and filter pads. The proteins from the SDS-PAGE gel were then blotted onto the 444 
PVDF membrane using a G2 semi-dry fast blotter (Pierce). After the membrane was 445 
blocked and subsequently washed, and the immunodetection steps were completed 446 
on a SNAP id 2.0 western blotting system (Merck Millipore) according to 447 
manufacturer’s instructions. The antibodies used include a polyclonal rabbit anti-C3d 448 
(Dako) and a polyclonal goat anti-rabbit IgG (H+L) HRP conjugated (Invitrogen). To 449 
detect the HRP conjugated antibody the membrane was incubated with ECL prime 450 
western blotting substrate (Amersham) and then imaged on a Fusion SL (VILBER) 451 
by chemiluminescence with molecular weight markers highlighted using a 452 
WesternSure pen (LI-COR). 453 
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Expression and purification of recombinant proteins 454 
The DNA sequence of human C3d (residues 1-310) comprised of C3 residues 996-455 
1303 (pre-pro C3 numbering) with a Cys to Ala mutation at position 17(C3d) /1010 456 
(pre-pro C3) (C3d17A) was previously cloned into the pET15b expression plasmid14. 457 
To reproduce the wild-type sequence, the Ala at position 17 of the C3d17A construct 458 
was reverted back to a Cys (C3d17C) using site-directed mutagenesis. Both C3d 459 
constructs were expressed in the Escherichia coli BL21(DE3) (Sigma Aldrich) or 460 
Shuffle T7 (NEB) cell lines and purified using cation exchange (column: HiTrap SP 461 
HP [GE Healthcare], binding buffer: 50 mM MES pH 5.5, elution buffer: 50 mM MES, 462 
500 mM NaCl pH 5.5) followed by size exclusion chromatography (column: HiLoad 463 
16/600 Superdex 200 prep grade [GE Healthcare], buffer: 20 mM Tris, 150 mM NaCl 464 
pH 7.4).  465 
The human CR2(SCR1-4)-Fc and FH19-20 constructs used in surface plasmon 466 
resonance experiments were expressed in Chinese hamster ovary (CHO) cells or 467 
Pichia pastoris respectively and purified as described previously (CR2(SCR1-4)-Fc: 468 
8; FH19-20: 61). The monomeric state of FH19-20 was confirmed using analytical 469 
ultracentrifugation (Supplementary Figure S9). 470 
 471 
Crystallisation, data collection and structure determination of dimeric C3d17C  472 
Crystallisation was performed at 18°C using the hanging drop vapour diffusion 473 
method. A 15 mg mL-1 (432 µM) C3d17C solution was subjected to a grid screen 474 
containing 100 mM Tris pH 8, 50-300 mM NaCl and 16-26% PEG 4000. Crystals 475 
appeared in the condition containing 100 mM Tris pH 8, 200 mM NaCl, 24% PEG 476 
4000, were mounted on loops, flash-frozen in liquid nitrogen and X-ray diffraction 477 
data collected on the IO4 beamline at the Diamond Light Source synchrotron 478 
(Oxfordshire, UK) (See Supplementary Table S1 for data collection statistics). 479 
Integration of Dectris PILATUS 6M pixel detector diffraction images and data 480 
reduction were performed using Xia2-DIALS and AIMLESS respectively. The 481 
automated BALBES pipeline and COOT were used for molecular replacement and 482 
model building. Refinement was carried out in REFMAC and Phenix (refinement 483 
statistics can be found in Supplementary Table S2) and UCSF Chimera was used 484 
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for superpositioning and generation of images. The structure of the C3d17C dimer is 485 
available on the PDB with the following accession code: 6RMT. 486 
Synthesis and characterisation of N,N'-(propane-1,3-diyl) bis(2-487 
bromoacetamide) linker 488 
 489 
A solution of K2CO3 (5.92 g, 42.8 mmol) in water (21 mL) was added to a solution of 490 
1,3-diaminopropane (1.06 g, 14.3 mmol) in chloroform (35 mL) at 5°C with stirring. A 491 
solution of bromoacetyl bromide (8.65 g, 42.8 mmol) in anhydrous chloroform (15 492 
mL) was then added dropwise to the mixture and the reaction was left stirring at 493 
room temperature for 18 hours. The resultant precipitate was filtered, washed with 494 
water (6 x 10 mL), and dried under vacuum to yield N,N'-(propane-1,3-diyl)bis(2-495 
bromoacetamide) as a white solid (2.45 g, 55%). Subsequent characterisation of the 496 
linker was performed using 1H-NMR (Supplementary Figure S4a) and 13C-NMR 497 
(Supplementary Figure S4b). High resolution electrospray ionisation time-of-flight 498 
mass spectrometry m/z: [M + Na]+ calculated for C7H12Br2N2O2Na = 338.9143 Da, 499 
338.9143 Da was observed. 500 
 501 
Production, purification and characterisation of chemically-linked C3d dimers 502 
For the generation of chemically-linked C3d17C dimers, small-scale trials were 503 
performed involving combination of C3d17C with the N,N'-(propane-1,3-diyl)bis(2-504 
bromoacetamide) linker in 0.1 M Tris, 0.15 M NaCl, 5 mM EDTA pH 7.5 at 0.55, 0.75 505 
or 1.0 molar equivalences. Following overnight incubation at room temperature 506 
(21°C), linker-mediated C3d17C dimerisation was confirmed using reducing SDS-507 
PAGE and electrospray time-of-flight mass spectrometry (Supplementary Figure 508 
S5). A larger scale reaction at 0.75 molar equivalence (3.75 mg C3d17C, 0.026 mg 509 
linker) was subsequently carried out as described above and subjected to size 510 
exclusion chromatography to separate the chemically-linked dimeric C3d17C from 511 
monomeric C3d17C (Supplementary Figures S6a and S6b). Particle size analysis 512 
yielded a single species (Supplementary Figure S6c), analytical ultracentrifugation 513 
confirmed the dimeric state of the chemically-linked C3d17C (Supplementary Figure 514 
S6d) and both biophysical techniques showed a lack of aggregate formation. 515 
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Chemically-linked dimeric C3d17C was subsequently digested with trypsin (Sigma 516 
Aldrich) (1:50 ratio) at 37°C over a time course (Supplementary Figure S6e). The 517 
digestion reaction was stopped by addition of a trypsin inhibitor (Sigma Aldrich) (1:2 518 
ratio). Electrospray ionization time-of-flight mass spectrometry of the trypsin-digested 519 
dimeric C3d17C fragments followed by analysis using the Masshunter Qualitative 520 
Analysis and BioConfirm (Agilent) software packages was used to confirm chemical 521 
linkage at position 17C of C3d (Supplementary Table S3) and the presence of an 522 
intact internal disulphide bond (Supplementary Table S4). 523 
 524 
Surface plasmon resonance  525 
All surface plasmon resonance experiments were performed on a Biacore S200 526 
sensor (GE Healthcare) at 25°C with HBST (10 mM HEPES, 150 mM NaCl, 0.005% 527 
Tween-20, pH 7.4) used as the running buffer. CR2-Fc and FH19-20 were prepared in 528 
10 mM sodium acetate pH 5 and immobilised at 300 RU (CR2-Fc: 20 µM, FH19-20: 529 
240 µM) to different flow cells of CM5 chips (GE Healthcare) using standard amine 530 
coupling involving preparation of the dextran matrix with 100 mM N-531 
hydroxysuccinimide (NHS) and 40 mM 1-ethyl-3-(dimethylaminopropyl) carbodiimide 532 
(EDC) followed by quenching with 1 M ethanolamine-HCl pH 8.5. Monomeric C3d17A 533 
and chemically-linked dimeric C3d17C used as analytes were prepared to a fixed 534 
concentration, serially diluted in HBST and injected in duplicate. 10 mM sodium 535 
acetate, 1 M NaCl pH 4 was used as the regeneration buffer but could not 536 
regenerate the chip surface of the highly avid interactions between dimeric C3d17C 537 
and CR2-Fc/FH19-20. Data were analysed using the Biacore S200 Evaluation 538 
Software 1.0. Responses from blank reference flow cells were subtracted from 539 
ligand-immobilised flow cells and all data were double-referenced (buffer inject 540 
subtracted).  541 
 542 
Flow cytometric analysis of B cell activation 543 
Human peripheral blood mononuclear cells (PBMC) were isolated from leukocyte 544 
cone blood collected from healthy volunteers (NHS Blood and Transplant Service), 545 
using density-gradient centrifugation in LeucosepTM tubes (Greiner-Bio-One). 546 
PBMCs were frozen and stored in liquid nitrogen in accordance with UCB Biopharma 547 
UK HTA License Number 12,504. Frozen PBMCs were thawed and diluted into cold 548 
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RPMI 1640 medium (Gibco) supplemented with 10% (v/v) foetal bovine serum, 1% 549 
(v/v) penicillin-streptomycin (Sigma Aldrich) and 1% (v/v) GlutaMAX (Gibco). For 550 
experiments on isolated B cells, B cells were purified from PBMCs by negative 551 
selection using the Miltenyi Biotec Human B Cell Isolation Kit II as per the 552 
manufacturer’s instructions. Following centrifugation, cells were counted, assessed 553 
for viability, which typically exceeded 90% for PBMCs and 80% for B cells, and re-554 
suspended to the desired density in ambient medium.   555 
PBMCs or B cells were then seeded onto sterile V-bottom plates at a density of 556 
150,000 or 40,000 cells/well respectively and allowed to recover at 37°C with 5% 557 
CO2 for 1h. Monomeric C3d17A or chemically-linked dimeric C3d17C were serially 558 
diluted in media and added to the cells in duplicate to give final concentrations 559 
ranging from 2 µM to 0.1 nM (based on the molecular weight of monomeric C3d17A 560 
for both constructs in order to control for the number of binding sites). Following a 30 561 
min incubation period with the C3d constructs, additions of either goat F(ab’)2 anti-562 
human IgM LE/AF (Southern Biotech) at a final concentration of 10 µg mL-1 or media 563 
were made and the cells incubated for a further 18h at 37°C with 5% CO2. 564 
After a period of cooling on ice, the cells were stained for 1h with the LIVE/DEAD™ 565 
fixable near-infrared dead cell stain (1:1000 dilution, Invitrogen) along with the 566 
following labelled antibodies diluted in an ice-cold staining buffer (PBS supplemented 567 
with 1% BSA, 2mM EDTA and 0.05% NaN3): PerCP-Cy™5.5 mouse anti-human 568 
CD19 (1:40 dilution, Clone HIB19, BD Pharmingen) (for PBMC samples only), FITC 569 
mouse anti-human CD40 (1:20 dilution, Clone 5C3, BD Pharmingen), Brilliant Violet 570 
421™ mouse anti-human CD69 (1:40 dilution, Clone FN50, BioLegend), PE mouse 571 
anti-human CD71 (1:20 dilution, Clone M-A712, BD Pharmingen) and APC mouse 572 
anti-human CD86 (1:20 dilution, Clone 2331, BD Pharmingen). The cells were 573 
subsequently washed and analysed on an Intellicyt® iQue Screener PLUS flow 574 
cytometer. The gating strategy applied for live, singlet CD19+ B cells and activation 575 
markers can be found in Supplementary Figures S12 and S13, respectively. 576 
Antibody capture beads were used for compensation. Data were expressed as mean 577 
values from at least 2 replicates ± standard deviation from the mean and depicted as 578 
scatter plots with curves fitted using a four-parameter variable slope non-linear 579 
regression model in GraphPad Prism (version 8.4.1). The geometric mean 580 
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fluorescence intensity for the monomer and dimer were compared at both 0.1 nM 581 
and 2000 nM C3d concentration using an analysis of variance on the log 582 
transformed fluorescence fitting donor as a fixed effect.  The downregulation of 583 
CD40 expression is expressed as a percentage reduction in fluorescence of the 584 
dimer compared to the monomer in the anti-IgM stimulated cells. 585 
 586 
Ca2+ influx experiments 587 
Intracellular Ca2+ measurements using flow cytometry were performed as described 588 
previously42,62,63. Briefly, isolated C57BL/6 mouse splenocytes maintained at 37°C 589 
were Indo 1-AM loaded, stained with a rat anti-mouse CD45R/B220-APC antibody 590 
(Clone RA3-6B2, BD Pharmingen) and analysed on a BD LSR II flow cytometer (BD 591 
Biosciences) at RT. 4 or 10 µg of monomeric C3d17A or chemically-linked dimeric 592 
C3d17C were added to the cells 30s after data acquisition. After 90s, cells were 593 
stimulated with a suboptimal concentration of pre-mixed complexes composed of 594 
0.056 µg mL-1 biotinylated F(ab’)2 goat anti-mouse IgM (µ-chain specific) (Jackson 595 
ImmunoResearch), ~3 µg mL-1 C3dg-biotin (produced in house) and ~1.3 µg mL-1 596 
streptavidin (aIgM-b/C3dg-b/ST). Experiments were run for 10 min and intracellular 597 
Ca2+ influx of gated B220+ cells was analysed using the FlowJo® software (FlowJo 598 




Data Availability 603 
 604 
The datasets generated and analysed during the current study are available from the 605 
corresponding authors on request. 606 
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Figure Legends 862 
 863 
Figure 1. Cleavage of C3 results in the spontaneous formation of disulphide-864 
linked C3b dimers. (a) Reducing Tris-Acetate SDS-PAGE (left panel) and anti-C3 865 
-chain western blot (right panel) analyses of serum-derived human C3 subjected to 866 
mild trypsin proteolysis at t=0 and t=2 minutes. Indicated are the intact and cleaved 867 
C3 -chains (120 and 111 kDa, respectively) and C3 -chain (75 kDa). Anti-C3 -868 
chain western blot analysis confirms the positions of the intact and cleaved C3 869 
chains (right panel). (b) Non-reducing Tris-Acetate SDS-PAGE (left panel) and anti-870 
C3 -chain western blot (right panel) analyses of human C3 subjected to mild trypsin 871 
proteolysis at t=0 and t=2 minutes. Indicated are intact and cleaved C3 (195 and 186 872 
kDa, respectively) as well as disulphide-linked C3b dimers (C3b2, right panel) and a 873 
faint band suggestive of a dimeric form of C3 (highlighted as C32 in grey font). Anti-874 
C3 -chain western blot analysis confirms the positions of intact C3 and monomeric 875 
and disulphide-linked dimeric C3b (right panel). Molecular weight markers shown are 876 
HiMark (M1) and PageRuler Plus (M2). Raw SDS-PAGE gel and western blot 877 
images can be found in Supplementary Figure S1. 878 
 879 
Figure 2. Structure of a disulphide-linked human C3d17C dimer at 2.0 Å 880 
resolution. (a) The ribbon diagram shows disulphide linkage of the monomeric 881 
subunits at position Cys17 results in the formation of a dimer 92.37 Å in length with a 882 
0.61 Å (chain A)/0.40 Å (chain B) main chain (M1-P294) RMSD relative to the 883 
structure of C3d17A (PDB:1C3D). (b) Enlarged view of the C3d17C dimer interface 884 
showing the side chains of helix α1 residues M1-C17. Inset: 2Fo-Fc electron density 885 
contoured at 1.0 σ of the partially broken C17-C17 interchain disulphide bond (2.07 886 
Å) resulting from oxidation of one conformer of Chain B Cys17. (c) Solid molecular 887 
surface representation of the C3d17C dimer in three different orientations rotated by 888 
90° angles counter-clockwise. PDB accession code: 6RMT. See Supplementary 889 
Tables S1 and S2 for data collection and refinement statistics.  890 
 891 
Figure 3. Dimeric C3d17C cross-links CR2 and FH19-20. (a) SPR sensorgrams 892 
showing serially-diluted concentrations of 250 nM monomeric C3d17A (left) or dimeric 893 
C3d17C (right) flowed in duplicate over flow cells of a CM5 senor chip immobilised 894 
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with CR2-Fc (top) or FH19-20 (bottom). The binding of C3d17A to CR2-Fc and FH19-20 895 
follows a conventional association-steady state-dissociation pattern while the binding 896 
of dimeric C3d17C to the same ligands generates an unusual two-state binding 897 
interaction. At concentrations up to the first 15.63 nM replicate (dashed line) the 898 
binding patterns depict highly avid interactions suggestive of the formation of dimeric 899 
C3d17C-CR2-Fc and dimeric C3d17C-FH19-20 crosslinked complexes which are not 900 
fully eluted from the surface. Thus, the subsequent injection cycles commence at a 901 
higher baseline response where the high avidity binding sites for dimeric C3d17C on 902 
CR2-Fc or FH19-20 remain saturated. This causes the binding mode to switch to less 903 
favourable, readily-disrupted interactions suggestive of the formation of 1:1 904 
complexes, although some crosslinked complexes persist. Inset: baseline-adjusted 905 
sensorgrams showing the less favourable 1:1 complexes (1 C3d17C dimer: 1 CR2-Fc 906 
or FH19-20 molecule) which form at higher concentrations of dimeric C3d17C (62.5-250 907 
nM) and are readily eluted from the surface. Arrows depict the regeneration period. 908 
See Supplementary Figure S7 for further details and Supplementary Figure S8 for 909 
results from an additional two independent experiments. (b) Schematic model 910 
depicting the proposed mechanistic basis behind dimeric C3d17C-mediated 911 
crosslinking of surface-associated CR2 (SCR 1-4). At low concentrations, C3d17C 912 
dimers crosslink two surface-associated CR2 (SCR 1-4) molecules via highly avid 913 
interactions involving the acidic residue-lined concave face of C3d and SCRs 1 and 914 
2 of CR2 (top). Once a critical threshold concentration has been surpassed, the 915 
increase in dimeric C3d17C molecules relative to available CR2 binding sites 916 
outcompetes the second binding site on C3d17C dimers and favours the formation of 917 
1:1 complexes (middle). Unlike C3d17C dimers, monomeric C3d17A lacks the ability to 918 
crosslink CR2 and is restricted to the formation of 1:1 complexes (bottom). (c) 919 
Superposition of SCR1-2 of CR2 (PDB accession code: 3OED) onto its binding sites 920 
on the C3d17C dimer demonstrating how dimeric C3d17C could crosslink CR2, as 921 
indicated by the SPR data gathered, at a structural level.  922 
 923 
Figure 4. Monomeric C3d17A and to a greater extent dimeric C3d17C alter the 924 
activation state of murine (a) and human (b) B cell populations. (a) Ca2+ influx 925 
experiment showing incubation with 4 µg C3d17A monomer or C3d17C dimer (30 s) 90 926 
seconds prior to the addition of BCR/CR2-crosslinking complexes (a-IgM-b/C3dg-927 
b/ST) (120 s) significantly retards and reduces Ca2+ influx in CD45R/B220-gated Indo 928 
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1-AM-loaded C57BL/6 mouse splenocytes with a more pronounced blocking effect 929 
apparent with dimeric C3d17C. 10 µg of either form of C3d completely eliminates Ca2+ 930 
influx (Supplementary Figure S11) suggesting the observed blocking effect is 931 
concentration dependent and likely a result of CR2 sequestration by monomeric 932 
C3d17A/dimeric C3d17C reducing the proportion of CR2 available for crosslinking with 933 
the BCR. BCR/CR2-crosslinking complexes were composed of a suboptimal dose 934 
(0.056 µg mL-1) of biotinylated F(ab’)2 goat anti‐mouse IgM (a-IgM-b), C3dg-biotin 935 
(C3dg-b) and streptavidin (ST). The C3d17A monomer/C3d17C dimer-mediated 936 
blocking of Ca2+ influx was not evident when higher, more optimal concentrations of 937 
a-IgM-b/ST were used or when all the reaction components were added 938 
simultaneously.  (b) Flow cytometric analysis of CD19+ B cells stimulated with 939 
monomeric C3d17A or dimeric C3d17C in the presence or absence of BCR-940 
crosslinking anti-IgM F(ab’)2 (10 µg mL-1) reveals C3d-induced changes in the 941 
expression of surface-associated B cell activation markers. While no C3d-mediated 942 
changes in CD71 expression are evident, at higher concentrations (> 3 nM) both 943 
monomeric C3d17A and dimeric C3d17C appear to downregulate CD40, with a more 944 
pronounced reduction in expression in the presence of dimeric C3d17C. Conversely, 945 
in the presence of anti-IgM, both monomeric C3d17A and to a greater extent dimeric 946 
C3d17C synergistically upregulate CD69 and CD86 although at concentrations > 10 947 
nM both forms of C3d are also capable of enhancing expression of these activation 948 
markers in the absence of anti-IgM. Data are of PBMC B cell populations from a 949 
representative donor and displayed as mean values (n=2) ± standard deviation from 950 
the mean with curves fitted using a non-linear regression model. Results from an 951 
additional two donors can be found in Supplementary Figure S14.   952 
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